Blood Group Genotyping for Sickle Cell and Thalassaemia
Estimated value
—
Awarded value
£141k
Awarded 14 May 2025
Suppliers
1
Lots
1
1 awarded
Published
05 Dec 2025
Description
Embedding blood group genotyping into routine practice. The primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping
Scope
- Reference
- C369873
- Commercial tool
- Standalone contract
Submission & procedure
- Procedure
- Direct award
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£141k
Award date
14 May 2025
Contract start
19 Dec 2025
Contract end
31 Mar 2026
Awarded to
NH